Viewing nowCombinationCelebica Tablet 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201505168 · Approved 2015.07.30 · Insurance code 693901800
Treatment of essential hypertension not controlled with monotherapy
This medication is used to treat patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It effectively lowers blood pressure, reduces the burden on the cardiovascular system, and helps decrease the risk of complications, thus playing an important role in hypertension management and improving health.
Take 1 tablet of this medicine once daily with water, with or without food. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medicine; however, if blood pressure is not controlled with monotherapy with the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this medicine to patients with severe hepatic impairment. (See section 2, “Patients in whom this medicine must not be administered,” under Precautions for Use.) ○ Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored closely and more frequently.
○ Children: The safety and efficacy in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. It should not be administered to patients who are allergic to its components, pregnant or breastfeeding women, patients with severe liver disease or certain heart conditions, patients undergoing renal dialysis, patients in shock, or certain diabetic patients. Patients with low blood pressure due to a lack of fluid or salt may experience low blood pressure symptoms when starting this medication; therefore, their condition should be closely monitored, and caution is needed as sudden vascular dilation can lead to hypotension. It should be administered with caution to patients with severe heart disease, congestive heart failure, reduced kidney function, or liver impairment. Various side effects may occur, including dizziness, headache, hypotension, edema, dyspepsia, rash, etc., so if symptoms occur, consult a doctor. Patients who suddenly discontinue beta-blockers should be cautious when taking this medication, and those combining it with other medications that can affect blood pressure and kidney function should be monitored closely. In principle, this medication should not be used during pregnancy, and anyone planning a pregnancy or currently pregnant should consult a doctor. Breastfeeding women should also stop breastfeeding or discontinue the medication as it may cause adverse reactions in infants. Safety and efficacy in children under 18 years have not been established and are therefore not recommended. Given the potential for impaired liver, kidney, and heart function in the elderly, it is advisable to start with a lower dose. In case of overdose, severe hypotension and symptoms due to vascular dilation may occur, so care should be taken not to exceed the recommended dose, and any unusual symptoms should prompt immediate medical attention. Store this medication in a tightly sealed container to prevent exposure to air or moisture. Also, keep it in a safe place at room temperature between 1°C and 30°C, away from excessive heat or cold.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to avoid exposure to air or moisture. It is safest to keep it at room temperature between 1°C and 30°C, away from excessive heat or cold.
Light yellow round film-coated tablet
28 tablets/Alu-Alu
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.